- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4196 - 1,2,4-Triazoles
Patent holdings for IPC class A61K 31/4196
Total number of patents in this class: 2925
10-year publication summary
|
218
|
183
|
227
|
253
|
236
|
211
|
184
|
178
|
188
|
125
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Synta Pharmaceuticals Corp. | 176 |
77 |
| Axsome Therapeutics, Inc. | 256 |
60 |
| F. Hoffmann-La Roche AG | 7920 |
49 |
| Novartis AG | 10829 |
48 |
| Karyopharm Therapeutics Inc. | 142 |
38 |
| Genentech, Inc. | 3983 |
31 |
| Merck Sharp & Dohme LLC | 3742 |
31 |
| Hoffmann-La Roche Inc. | 3428 |
30 |
| Bayer Pharma AG | 1047 |
30 |
| Boehringer Ingelheim International GmbH | 4644 |
28 |
| Ardea Biosciences, Inc. | 72 |
28 |
| Gilead Sciences, Inc. | 2038 |
27 |
| Bristol-myers Squibb Company | 4884 |
24 |
| Pfizer Inc. | 3380 |
23 |
| The Regents of the University of California | 19943 |
21 |
| Havah Therapeutics Pty Ltd | 21 |
20 |
| Eli Lilly and Company | 3848 |
19 |
| BASF SE | 20915 |
18 |
| Board of Regents, The University of Texas System | 5798 |
18 |
| Rigel Pharmaceuticals, Inc. | 538 |
18 |
| Other owners | 2287 |